Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

6.7%

2 terminated/withdrawn out of 30 trials

Success Rate

92.3%

+5.8% vs industry average

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

0%

0 of 24 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
13(44.8%)
Phase 2
12(41.4%)
N/A
2(6.9%)
Phase 3
2(6.9%)
29Total
Phase 1(13)
Phase 2(12)
N/A(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (30)

Showing 20 of 30 trials
NCT00742443Phase 3Completed

Juvista in Scar Revision Surgery of Disfiguring Scars

Role: lead

NCT01115868Phase 1Unknown

Prevascar in African Continental Group Scarring

Role: lead

NCT01014494Not ApplicableUnknown

Adaprev in Digital Flexor Tendon Repair

Role: lead

NCT01029158Phase 1Completed

A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo

Role: lead

NCT00836147Phase 1Completed

Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids

Role: lead

NCT00821457Not ApplicableWithdrawn

Juvista in the Non-surgical Improvement of Existing Scars

Role: lead

NCT00430326Phase 2Completed

Juvista (Avotermin) in Scars Following Varicose Vein Removal

Role: lead

NCT00710333Phase 1Completed

Safety of Juvista When Administered Following Excision of Ear Lobe Keloids

Role: lead

NCT00984854Phase 1Completed

Investigation Into the Safety of Intradermal Juvidex (M6P) Administered to Wounds of Healthy Subjects

Role: lead

NCT00984516Phase 2Completed

Investigation Into the Safety and Scar-improvement Efficacy of Intradermal Juvidex Dosed Once or Three Times

Role: lead

NCT00984503Phase 2Completed

Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites

Role: lead

NCT00984386Phase 2Completed

Investigation of the Efficacy of Zesteem in Accelerating Early Wound Healing

Role: lead

NCT00984646Phase 2Completed

Investigation Into the Scar Reduction Potential of Prevascar (Interleukin-10)

Role: lead

NCT00984581Phase 1Completed

Safety and Efficacy Study of Avotermin (Juvista) in Female Subjects

Role: lead

NCT00977951Phase 1Completed

Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects

Role: lead

NCT00978302Phase 1Completed

Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)

Role: lead

NCT00978367Phase 1Completed

Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)

Role: lead

NCT00469235Phase 1Completed

Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars

Role: lead

NCT00426972Phase 3Completed

Trial of Zesteem (Estradiol) in Healing of Split Thickness Skin Graft Donor Sites

Role: lead

NCT00847795Phase 1Completed

Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.

Role: lead